NCT04502680Unknown2 期
A Multicenter, Randomized, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Maintenance Treatment With Eribulin Mesylate Following Standard Adjuvant Chemotherapy in Triple Negative Breast Cancer Patients
The First Affiliated Hospital with Nanjing Medical University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2021年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Disease Free Survival (DFS)
研究概览
简要总结
This clinical trial is a multicenter, randomized, open-label, phase-II study to evaluate the efficacy and safety of maintenance treatment with eribulin mesylate following standard adjuvant chemotherapy in triple negative breast cancer patients.
详细描述
Triple negative breast cancer (TNBC) is an aggressive disease with high relapse rates and poor overall survival. This study explores the role of maintenance treatment with eribulin following standard adjuvant chemotherapy in TNBC. Patients will be randomized to receive eribulin mesylate maintenance treatment or observation after standard adjuvant chemotherapy.
The primary objective is to evaluate the disease free survival (DFS). The secondary objective is to evaluate the overall survival (OS), objective response rate (ORR) and the safety of eribulin mesylate maintenance treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •The patient volunteers and signs an informed consent form;
- •Age ≥18 years old, female;
- •The patient was diagnosed as triple-negative breast cancer by histopathology (ER negative (IHC ER positive percentage <1%), PR negative (IHC PR positive percentage <1%), HER2 negative (IHC-/+ or IHC++ but FISH/CISH- )), and there is no evidence of metastasis;
- •Patients underwent radical or breast conserving surgery combined with sentinel lymph node biopsy for primary breast cancer. Margins free of disease and ductal carcinoma in-situ (DCIS) are required. Lobular carcinoma is not considered a positive margin.
- •For patients who have previously received neoadjuvant therapy for triple-negative breast cancer containing anthracyclines and taxanes, the postoperative efficacy evaluation did not reach pathological complete remission (non-PCR), that is, the primary breast and/or metastatic regional lymph nodes still have histological evidence of malignant tumors other than carcinoma in situ;
- •For patients who have not received neoadjuvant therapy for triple-negative breast cancer, ≥1 ipsilateral axillary lymph nodes have pathological tumor involvement after surgery. Or the patient's postoperative lymph nodes are negative, but at least meet one of the following conditions:
- •Primary invasive tumor size> 2cm in pathology;
- •Ki-67 index of untreated breast tissue>30%;
- •The comprehensive score is at least 8 points (Elston and Ellis 1991) according to the improved Bloom-Richardson grading system (also known as the Nottingham scale), which belongs to the 3rd level;
- •Physical condition ECOG PS: 0-1;
- •Previously received adjuvant chemotherapy consisting of a minimum of 6 courses with anthracyclines combined taxanes;
- •Time window between end of adjuvant chemotherapy and study randomization must be less than 8 weeks. In patients receiving adjuvant radiotherapy, time window allowed between last session and randomisation is 4 weeks;
- •Laboratory tests meet the following criteria:
- •Bone marrow function: absolute count of blood neutrophils (ANC) ≥1.5×109/L; platelet (PLT)≥100×109/L; hemoglobin (HB)≥90g/L;
- •Liver function: serum total bilirubin (STB), combined bilirubin (CB) ≤ upper limit of normal (ULN) *1.5; alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ULN*2.5;
- •Renal function: serum creatinine (Cr) ≤ ULN; endogenous creatinine clearance (Ccr) ≥ 60 ml / min (calculated using the Cockcroft-Gault formula).
排除标准
- •Patients with metastatic breast cancer (including contralateral axillary lymph nodes), inflammatory carcinomas;
- •Previous breast cancer history (except for ipsilateral DCIS that only received local treatment ≥5 years ago), malignant tumors of other histological origins (except for non-melanoma skin cancer or cervical carcinoma in situ) unless the patient's tumor had been completely alleviated and had not received treatment for at least 5 years before the enrollment date;
- •Major surgery within 4 weeks prior to enrollment, or surgical wounds have not healed;
- •Embolization and bleeding occurred within 4 weeks before enrollment;
- •Severe cardiovascular disease, including hypertension (BP≥160/95mmHg) uncontrolled by medical treatment, unstable angina, history of myocardial infarction in the past 6 months, congestive heart failure>NYHA II, severe heart rhythm Abnormalities and pericardial effusions;
- •Severe infection requires intravenous antibiotic, antifungal or antiviral treatment;
- •Suffering from mental illness, poor compliance;
- •Researchers believe that it is not suitable for inclusion.
研究组 & 干预措施
Eribulin Mesylate
Experimental
Patients receive eribulin mesylate following standard adjuvant chemotherapy.
干预措施: Eribulin Mesylate (Drug)
结局指标
主要结局
Disease Free Survival (DFS)
时间窗: 3 years
DFS was measured from the date of randomization assignment in the intent to treat (ITT) population to loco-regional or distant recurrence, second primary malignancy or death date, whichever occurred first.
次要结局
- Objective Response Rate (ORR)(3 years)
- Overall Survival(3 years)
- The Number of Participants Who Experienced Adverse Events (AE)(3 years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-DaraMultiple MyelomaNCT03896737European Myeloma Network B.V.401
招募中
2 期
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT06558227Suzhou Zelgen Biopharmaceuticals Co.,Ltd90
Unknown
2 期
Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical ResectionHepatocellular Carcinoma (HCC)NCT05213637Chinese PLA General Hospital430
撤回
2 期
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical CancerCervical CancerNCT05033132Agenus Inc.
已完成
2 期
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung CancerLung Cancer, Non-Small CellNCT01362296GlaxoSmithKline134